Skip to content

Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities

Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04583683
Acronym
ARGOS
Enrollment
218
Registered
2020-10-12
Start date
2020-09-30
Completion date
2022-09-30
Last updated
2021-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery Candidate, Diet, Healthy, Obesity, Obesity, Morbid

Brief summary

It is a prospective randomized trial on 218 subjects, 109 for each arms. The purpose of this trial is to compare very low calorie diet and metabolic surgery induced weight loss and its maintenance.

Detailed description

Obesity is a leading public health issued associated with poor quality of life, morbidity and an increased mortality rate. Although metabolic surgery results in a greater weight loss when compared to non-surgical approaches, a low calorie diet associated with intensive maintenance session may be a valid alternative for weight loss. Since lifestyle interventions are safer and potentially more cost effective than metabolic surgery, this trial will test whether an intensive lifestyle intervention is as effective as metabolic surgery to induce weight loss and its maintenance. A total of 218 participants will be randomly assigned to metabolic surgery (109) or intensive lifestyle intervention (109). Clinical outcomes will be assessed at 25% reduction in Body Mass Index (BMI), at 12 months and 24 months.

Interventions

BEHAVIORALVery low calorie diet with Fortimel (Nutricia) supplementation

Patients will undergo a very low calorie diet

PROCEDUREMetabolic Surgery

Patients will undergo metabolic surgery

Sponsors

Catholic University of the Sacred Heart
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

* Aged between 19 and 69 years * Body Mass Index ≥35 kg/m2 and at least one or more obesity-related co-morbidities such as type II diabetes (T2DM), hypertension, sleep apnea and other respiratory disorders, non-alcoholic fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or heart disease * Body Mass Index ≥40 kg/m2

Exclusion criteria

* Pregnancy * Active cancer * End stage renal failure * End stage liver failure * Being unable to understand and sign informed consent

Design outcomes

Primary

MeasureTime frame
Time to achieve a 25% reduction in Body Mass Index1-12 months

Secondary

MeasureTime frame
Time to achieve 25% reduction in Body Mass Index1-24months
Change in body composition (lean mass-all tissues in the body except bone and fat-fat mass, bone density and visceral fat) using dual energy X-ray absorptiometry (DXA), from baseline, at 25% weight loss, at 12 months follow up and at 24 months follow up1-24months
Change in glycated hemoglobin (HbA1c), from baseline, at 12 and 24 months follow up (patients with diabetes)1-24months
Change in fasting glucose and fasting insulin, from baseline, at 12 and 24 months follow up1-24months
Percentage of participants who achieve 25% reduction in Body Mass Index1-12 months
Change in blood pressure, from baseline, at 12 and 24 months follow up1-24months
Change in total, HDL, LDL and total cholesterol from baseline, at 12 and 24 months follow up1-24months
Change in triglycerides from baseline, at 12 and 24 months follow up1-24months
Percentage of participants who maintain weight loss at 24 months follow up1-24months
Change in insulin resistance (assessed by HOMA-IR), from baseline, at 12 and 24 months follow up1-24months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026